C3d-binding assay for the detection of complement activating HLA antibodies: A useful tool for allocation to highly sensitised recipients in the post-CDC era?
Zo Ee WongJonathan DowningDianne De SantisMegan HalseSamuel BruceLinh TruongPatricia MartinezLloyd J D'OrsognaPublished in: HLA (2023)
This study confirms that the C3d-binding assay predicts actual CDC crossmatch results accurately. In particular, the high negative predictive value of the C3d-binding assay may be extremely useful to define HLA antibodies that do not activate complement in highly sensitised recipients. This article is protected by copyright. All rights reserved.